{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:43Z","timestamp":1792123663766,"version":"4.4.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the associations between the use of immune checkpoint inhibitors (ICIs) and the risk of developing uveitis among cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cancer patients who received ICI therapy and a comparison group of cancer patients who did not receive ICI therapy were retrospectively recruited from the TriNetX electronic heath-record registry. The outcome of interest was the development of new-onset uveitis. Propensity score matching based on a 1:1 ratio was conducted in order to reduce bias. Multi-variate cox proportional hazard models and Kaplan Meier method were also utilized to assess for the risk of uveitis among cancer patients who received ICI therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>71931 cancer patients (54.7% male; 76.5% white; mean age at index 63.6 \u00b1 12.2 years) who received ICI treatment (ICI group) and 71931 cancer patients (54.7% male; 77% white; mean age at index 63.5 \u00b1 12.4 years) who never received ICI (comparison group) were recruited. Associated Kaplan-Meier curves showed significantly increased uveitis risk among the ICI group for all follow-up years (p&amp;lt;0.001). The risk of uveitis was also higher among the ICI group during the 144-month follow-up period with a hazard ratio (HR) of 2.39 (95% CI: 2.07-2.75). Increased risk for specific uveitis diseases, such as iridocyclitis, chorioretinal inflammation, retinal vasculitis, unspecified purulent endophthalmitis, pan-uveitis and sympathetic uveitis were found. Subgroup analysis demonstrated an elevated hazard ratio for the development of uveitis among ICI recipients, spanning individuals below the age of 65 as well as those aged 65 and older. The elevated hazard ratio for uveitis development among ICI recipients was also observed across all genders, among those of white and Asian ethnicities, those with smoking history, and those with comorbid conditions such as hypertension and dyslipidemia, in comparison to their non-ICI counterparts. An additional subgroup analysis on monotherapy versus combinatory ICI regimens was also conducted. Individuals who received monotherapy from the class of anti-PD-1 (HR:1.98 [CI: 1.65-2.37]) and anti-CTLA-4 (HR:5.86 [CI:1.99-17.24]) exhibited elevated hazard ratios for uveitis development compared to their non-ICI comparators. Those exposed to combinatory ICI regimens, specifically a combination of anti-PD-1 and anti-CTLA4 (HR: 5.04 [CI:3.55-7.16]), showed increased hazard ratios for uveitis development compared to their non-ICI comparators. In contrast, individuals exposed to a combination of anti-PD-1 and anti-PD-L1 (HR: 2.47 [CI:0.81-7.50]) did not demonstrate an increased risk for uveitis compared to their non-ICI comparators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A significantly increased risk for uveitis diseases was found among the ICI group from the first year of follow-up. Increased awareness should be promoted on the occurrence of uveitis among cancer patients receiving ICI therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1302293","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:25:52Z","timestamp":1704774352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database"],"prefix":"10.3389","volume":"14","author":[{"given":"Hou-Ting","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Y.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Yi","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695904","article-title":"Epidemiology and risk factors in non-infectious uveitis: A systematic review","volume":"8","author":"Joltikov","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_816_20","article-title":"Drug-induced uveitis: A review","volume":"68","author":"Agarwal","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002181","article-title":"CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e29188","DOI":"10.1002\/jmv.29188","article-title":"The risk assessment of uveitis after COVID-19 diagnosis: A multicenter population-based study","volume":"95","author":"Hsia","year":"2023","journal-title":"J Med Virol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/v15020444","article-title":"Human immunodeficiency virus and uveitis","volume":"15","author":"Yang","year":"2023","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2290836","DOI":"10.1080\/22221751.2023.2290836","article-title":"Prevalence of uveitis in syphilis patients in Taiwan","author":"Chen","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3390\/jcm12093194","article-title":"Sarcoidosis-related uveitis: A review","volume":"12","author":"Giorgiutti","year":"2023","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ajo.2008.08.019","article-title":"Uveitis in patients with autoimmune hepatitis","volume":"147","author":"Lim","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S179182","article-title":"Psoriasis and uveitis: links and risks","volume":"9","author":"Fotiadou","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.2249","article-title":"Association of systemic lupus erythematosus with uveitis","volume":"133","author":"Gallagher","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.40568","article-title":"The eyes have it: A rheumatologist\u2019s view of uveitis","volume":"70","author":"Rosenbaum","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/children8080646","article-title":"Juvenile idiopathic arthritis associated uveitis","volume":"8","author":"Carlsson","year":"2021","journal-title":"Children (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1976213","article-title":"Chronic kidney disease as A potential risk factor for uveitis: A 13-year nationwide population-based cohort study in Taiwan","volume":"30","author":"Lin","year":"2022","journal-title":"Ocul Immunol Inflammation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2019.60308","article-title":"Beh\u00e7et\u2019s uveitis: current diagnostic and therapeutic approach","volume":"50","author":"\u00c7akar \u00d6zdal","year":"2020","journal-title":"Turk J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0161-6420(97)30361-3","article-title":"Scleritis-associated uveitis","volume":"104","author":"Sainz de la Maza","year":"1997","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2023.2232444","article-title":"Tinnitus as a potential risk factor for uveitis: A 14-year nationwide population-based cohort study in Taiwan","author":"Chen","year":"2023","journal-title":"Ocul Immunol Inflammation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.2045","article-title":"Assessing the uniformity of uveitis clinical concepts and associated ICD-10 codes across health care systems sharing the same electronic health records system","volume":"139","author":"McKay","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1781902","article-title":"Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes","volume":"29","author":"Dow","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102454","DOI":"10.1016\/j.jaut.2020.102454","article-title":"Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database","volume":"111","author":"Anquetil","year":"2020","journal-title":"J Autoimmun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.3390\/jcm11174993","article-title":"Ocular inflammation induced by immune checkpoint inhibitors","volume":"11","author":"Chaudot","year":"2022","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American academy of ophthalmology intelligent research in sight registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/02713680802233968","article-title":"Vogt-koyanagi-harada syndrome","volume":"33","author":"Fang","year":"2008","journal-title":"Curr Eye Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","article-title":"Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review","volume":"13","author":"Golder","year":"2016","journal-title":"PloS Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"Cd002068","DOI":"10.1002\/14651858.CD002068","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","volume":"2002","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.19-26775","article-title":"TRPM1 autoantibodies in melanoma patients without self-reported visual symptoms","volume":"60","author":"Duvoisin","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2022.2159447","article-title":"Characteristics of ocular inflammatory side effects associated with immune checkpoint inhibitors in a Northern California population","author":"Qian","year":"2023","journal-title":"Ocul Immunol Inflammation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","article-title":"Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous Malignant melanoma","volume":"5","author":"Matsuo","year":"2017","journal-title":"Clin Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.026","article-title":"Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small cell lung cancer","volume":"13","author":"Tamura","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J Immunother"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13580","DOI":"10.1038\/s41598-023-40565-z","article-title":"HLA-DRB1*04:05 is involved in the development of Vogt\u2013Koyanagi\u2013Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"13","author":"Takeuchi","year":"2023","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.3390\/cells11193072","article-title":"Increased adipose tissue expression of IL-23 associates with inflammatory markers in people with high LDL cholesterol","volume":"11","author":"Kochumon","year":"2022","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3463104","DOI":"10.1155\/2016\/3463104","article-title":"The role of interleukin-23 in the early development of emphysema in HIV1+ Smokers","volume":"2016","author":"Barjaktarevic","year":"2016","journal-title":"J Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.05.017","article-title":"Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study","volume":"44","author":"Berg","year":"2014","journal-title":"Semin Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.preteyeres.2020.100866","article-title":"Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis","volume":"80","author":"Zhong","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17906","article-title":"Clinical manifestations and outcome of syphilitic uveitis","volume":"57","author":"Bollemeijer","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S352608","article-title":"Ocular manifestations of Buerger\u2019s disease - A review of current knowledge","volume":"16","author":"Szyde\u0142ko-Pa\u015bko","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.16639","article-title":"Ophthalmologic manifestations of rheumatic diseases","volume":"30","author":"Hamideh","year":"2001","journal-title":"Semin Arthritis Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41433-021-01486-1","article-title":"Risk factors associated with post-operative uveitis after cataract surgery: a retrospective case-control study","volume":"36","author":"Halim","year":"2022","journal-title":"Eye (Lond)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04415-x","article-title":"Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis","volume":"257","author":"Coulon","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.3390\/jcm9123894","article-title":"Factors associated with ocular and extraocular recovery in 143 patients with sarcoid uveitis","volume":"9","author":"Bienvenu","year":"2020","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J Neurooncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1302293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:25:55Z","timestamp":1704774355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1302293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2023.1302293"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1302293","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"article-number":"1302293"}}